EBV在鼻咽癌细胞中呈克隆性扩增，为II型潜伏感染模式，主要表达病毒潜伏膜蛋白。我们前期通过单细胞测序和生物信息技术，预测和筛选得到鼻咽癌中EBV基因编码的候选病毒抗原LMP2A/2B，几乎在所有癌细胞中高表达，并参与鼻咽癌的转化、发生及发展等。但对鼻咽癌中LMP2A/2B抗原的特异性表位的筛选、鉴定及应用仍不清楚。本研究拟系统地筛选并鉴定出LMP2A/2B抗原的HLA-I型限制性相关的CD8+ CTL表位，使用四聚体染色技术，分选出表位肽特异性T细胞，并使用单细胞测序技术克隆出TCRα和β链，然后构建稳定表达TCRα/β的PBMCs，用于反验证表位肽的特异性和亲和力，继而进行动物实验以验证和探讨其杀伤作用和机制。因此，对于这种EBV特异性抗原表位的筛选、鉴定及TCR-T的设计，对于研究如何识别、预防和治疗相关于EBV感染的鼻咽癌意义深刻，并为后续新型疫苗的研发等提供充分的科学依据。

EBV (Epstein-Barr virus) shows clonal amplification in nasopharyngeal carcinoma (NPC) cells, which is a type II latent infection mode and mainly expresses viral latent membrane proteins. In previous studies, we predicted and screened the candidate virus antigen LMP2A/2B encoded by EBV gene in NPC through single-cell sequencing and bio-information technology, which was highly expressed in almost all carcinoma cells and involved in the transformation, occurrence and development of NPC. However, the screening, identification and application of specific epitopes of LMP2A/2B virus antigen in NPC remain unclear. In this study, we systematically intend to screen and identify the HLA-I type restricted associated CD8+ CTL epitopes from the LMP2A/2B. And then using tetramer staining, we identify T cells specifcally recognizing LMP2A/2B epitopes from PBMCs and clone the T cell receptor (TCR) α and β chains using a single-cell cloning technique. By expressing the paired TCRα/β genes in human primary T cells, we generate TCR-T cells for verification of the specificity and affinity of epitopes. Finally, we carry out the animal experiments to verify and discuss its killing effects and mechanisms. Therefore, the screening and identification of EBV-specific antigen epitopes and the design of TCR-T have profound significance for the research on how to identify, prevent and treat NPC associated with EBV infection, and provide sufficient scientific basis for the subsequent research and development of new vaccines.